The firm is currently evaluating the fairness of the sale of Element Solutions, Inc. (NYSE: ESI) to Solstice Advanced Materials, Inc. Under the proposed terms, Element Solutions shareholders are set to receive $10.00 in cash plus 0.500 shares of Solstice common stock, ultimately holding approximately 44% of the combined entity. Simultaneously, the firm is investigating the $85.00-per-share cash acquisition of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by Vertex Pharmaceuticals Incorporated.

Additional inquiries target the merger between Solstice Advanced Materials, Inc. (NASDAQ: SOLS) and Element Solutions, alongside the deal between Patrick Industries, Inc. (NASDAQ: PATK) and LCI Industries. In the latter transaction, Patrick shareholders are expected to retain a 52% stake in the resulting company. Investors holding common stock in these entities are encouraged to contact Juan Monteverde at jmonteverde@monteverdelaw.com or (212) 971-1341 to discuss potential concerns regarding these transactions.